source
- Aclaris scratches TSLP program from pipeline after flunking phase 2 eczema testA phase 2 study of Aclaris Therapeutics’ bosakitug in atopic dermatitis has missed its primary endpoint, adding to the setbacks anti-TSLP antibodies have encountered in the indication.Fierce Biotech · 6h ago↗ source
- FDA rejects Summit and Akeso's ivonescimab for narrow lung cancerThe U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…